Evidence map›Paper›PMID 41826300›Full record

ArticleNature communications2026

Hypusination of the translation factor eIF5A regulates mitochondrial tRNA processing to promote prostate cancer aggressiveness.

Michel Kahi, Abigail Mazzu, Ludovic Batistic, Marc Pujalte-Martin, Victor Tiroille, Anne Vincent, Joseph Murdaca, Loic Trapani, Paraskevi Kousteridou, Oumayma Benaceur and 22 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Michel KahiInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Abigail MazzuInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Ludovic BatisticInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.ORCID http://orcid.org/0000-0002-3732-0783
Marc Pujalte-MartinInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Victor TiroilleThe Hubrecht Institute, Utrecht, Netherlands.
Anne VincentINSERM U1052/CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0003-4616-7685
Joseph MurdacaInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Loic TrapaniUniversité Côte d'Azur, Faculté de Médecine, Nice, France.
Paraskevi KousteridouInserm U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
Oumayma BenaceurInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.ORCID http://orcid.org/0009-0002-4782-1140
Amine BelaidInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Marie IrondelleInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Emilie ThomasINSERM U1052/CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.
Christelle BoscagliUniversité Côte d'Azur, UAR Centre Commun de Microscopie Appliquée (CCMA), Nice, France.
Pierre BertrandInserm U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.ORCID http://orcid.org/0009-0004-6186-2349
Heather S CarrDepartment of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, USA.
Frédéric LarbretInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Emilie BaudeletInserm U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.
Stéphane AudebertInserm U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.ORCID http://orcid.org/0000-0002-9409-2588
Didier F PisaniUniversité Côte d'Azur, Faculté de Médecine, Nice, France.ORCID http://orcid.org/0000-0001-5879-8527
Silvère BaronUniversité Clermont Auvergne, iGReD, CNRS UMR 6293/INSERM U1103, Clermont-Ferrand, France.ORCID http://orcid.org/0000-0002-4524-3087
Luc CamoinInserm U1068, Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France.ORCID http://orcid.org/0000-0002-1230-4787
Mathieu CarlierInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Matthieu DurandUniversité Côte d'Azur, Faculté de Médecine, Nice, France.
Damien AmbrosettiUniversité Côte d'Azur, Faculté de Médecine, Nice, France.ORCID http://orcid.org/0000-0001-8665-0546
Yu ChenMemorial Sloan Kettering Cancer Center, New-York, USA.ORCID http://orcid.org/0000-0002-0171-3884
Jean-Jacques DiazINSERM U1052/CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France.
Arnaud JacquelInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.
Issam Ben-SahraDepartment of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, USA.ORCID http://orcid.org/0000-0001-9333-4162
Nathalie M MazureInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.ORCID http://orcid.org/0000-0003-1350-7161
Pascal PeraldiInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France.ORCID http://orcid.org/0000-0003-0205-9252
Frédéric BostInserm U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Nice, France. frederic.bost@univ-cotedazur.fr.ORCID http://orcid.org/0000-0003-4509-4701

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Institut National Du Cancer (French National Cancer Institute) PLBio 25-062 and 22-095Ligue Contre le Cancer Equipe Labelisée 2022NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Protein synthesis plays a central role in cancer development and progression. eukaryotic initiation factor 5 A (eIF5A), a translation factor activated by hypusination, is implicated in tumorigenesis, however, its mode of action is still unclear. We find that hypusinated eIF5A (eIF5A

Indexed as

Eukaryotic Translation Initiation Factor 5ALysineMitochondriaProstatic NeoplasmsRNA, MitochondrialRNA, TransferAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceMitochondrial ProteinsProtein BiosynthesisRNA Processing, Post-TranscriptionalEukaryotic Translation Initiation Factor 5AhypusineLysineMitochondrial ProteinsRNA, MitochondrialRNA, Transfer

Identifiers

PMID41826300
PMCPMC13230981

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.